RESEARCH PAPER
Research into analgesic effect of ondansetron in persistent pain model in rats with central noradrenergic system lesion
1
The Jan Grodek Higher Vocational State School in Sanok, Medical Institute, Poland
2
Department of Paediatrics, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia in Katowice, Poland
3
Medical University of Silesia School of Pharmacy with the Division of Laboratory Medicine Department of Toxicology, Sosnowiec, Poland
4
Toxicology and Drug Addiction Division, Department of Toxicology and Health Protection, Public Health Faculty, Medical University of Silesia in Katowice, Poland
Corresponding author
Wojciech Roczniak
The Jan Grodek Higher Vocational State School in Sanok, Medical Institute, Mickiewicza 21, 38-500 Sanok, Poland
The Jan Grodek Higher Vocational State School in Sanok, Medical Institute, Mickiewicza 21, 38-500 Sanok, Poland
J Pre Clin Clin Res. 2015;9(2):140-144
KEYWORDS
the central serotoninergic systemlesion to the central noradrenergic systemondansetronanalgesic effect
ABSTRACT
Introduction:
Many known substances affecting the serotoninergic system induce definite physiological effects, including those which are therapeutic. For instance, the enhanced serotoninergic transmission due to decreased functions of autoreceptors and increased inhibitory functions of postsynaptic 5-HT1A is associated with antidepressant effect. The central serotoninergic system takes part in the regulation of many bodily functions, such as sleep, wakefulness, blood pressure, pain perception or sexual behaviours. Moreover, it is involved in the pathogenesis of depression, anxiety, addictions, migraine and other headaches. In pain therapy, not only typical analgesics are used, but also substances without obvious analgesic effect, thus allowing potential pharmacological modulation of analgesic activity in the treatment of pain.
Objective:
The aim of the study was to determine whether a chemical lesion to the central noradrenergic system at an early stage of individual development alters reactivity of 5-HT3 receptors in adult rats.
Material and Methods:
The study used newborn and adult Wistar rats aged 8–10 weeks. Behavioural tests (writhing test, formalin assay) were used to assess the analgesic action of ondansetron as a 5-HT3 receptor antagonist.
Results:
The analgesic effect of ondansetron (1.0 mg/kg b.w., i.p.) in the writhing test was weak and short. Pain intensity score after ondansetron injection (1.0 mg/kg b.w., i.p) was 2–3 points and did not differ significantly between the study groups.
Conclusions:
Damage to the central noradrenergic system at an early stage of individual development has no effect on the antinociceptive effects of the serotonin (5-HT3) receptor antagonist, ondansetron, in the persistent pain mode
Many known substances affecting the serotoninergic system induce definite physiological effects, including those which are therapeutic. For instance, the enhanced serotoninergic transmission due to decreased functions of autoreceptors and increased inhibitory functions of postsynaptic 5-HT1A is associated with antidepressant effect. The central serotoninergic system takes part in the regulation of many bodily functions, such as sleep, wakefulness, blood pressure, pain perception or sexual behaviours. Moreover, it is involved in the pathogenesis of depression, anxiety, addictions, migraine and other headaches. In pain therapy, not only typical analgesics are used, but also substances without obvious analgesic effect, thus allowing potential pharmacological modulation of analgesic activity in the treatment of pain.
Objective:
The aim of the study was to determine whether a chemical lesion to the central noradrenergic system at an early stage of individual development alters reactivity of 5-HT3 receptors in adult rats.
Material and Methods:
The study used newborn and adult Wistar rats aged 8–10 weeks. Behavioural tests (writhing test, formalin assay) were used to assess the analgesic action of ondansetron as a 5-HT3 receptor antagonist.
Results:
The analgesic effect of ondansetron (1.0 mg/kg b.w., i.p.) in the writhing test was weak and short. Pain intensity score after ondansetron injection (1.0 mg/kg b.w., i.p) was 2–3 points and did not differ significantly between the study groups.
Conclusions:
Damage to the central noradrenergic system at an early stage of individual development has no effect on the antinociceptive effects of the serotonin (5-HT3) receptor antagonist, ondansetron, in the persistent pain mode
REFERENCES (35)
1.
McAllister-Williams RH, Ferreir IN, Young AH. Mood and neuropsychological function in depression: the role of corticosteroids and serotonin. Psychol Med. 1998; 28: 573–584.
2.
Van de Kar LD. Neuroendocrine pharmacology of serotonergic (5-HT) neurons. Ann Rev Pharmacol Toxicol. 1991; 31: 289–320.
3.
Fuller RW. Serotonin receptors and neuroendocrine responses. Neuropsychopharmacol. 1990; 3: 495–502.
4.
Tison F, Normand E, Jaber M, Aubert I, Bloch B. Aromatic L-amino-acid decarboxylase (DOPA decarboxylase) gene expression in dopaminergic and serotoninergic cells of the rat brainstem. Neurosci Lett. 1991; 127: 203–206.
5.
Cowen PJ. Cortisol, serotonin and depression: All stressed out? Brit J Psychiatry. 2002; 180: 99–100.
6.
Bauer MS, Frazer A. Mood disorders. In A. Frazer, PB Molinoff A Winokur Biological basis of brain function and disease. New York: Raven, 1994.
7.
Strickland PL, Deakin JF, Percival C, Dixon J, Gater RA, Goldberg DP. Biosocial origins of depression in the community. Interactions between social adversity, cortisol and serotonin neurotransmission. Brit J Psychiatry. 2002; 180: 168–173.
8.
Mann JJ, McBride PA, Brown RP i wsp. Relationship between central and peripheral serotonin indexes in depressed and suicidal psychiatric inpatients. Arch Gen Psychiatry. 1992; 49: 442–446.
9.
Roggenbach J, Muller-Oerlinghausen B, Franke L, Uebelhack R, Blank S, Ahrens B. Peripheral serotonergic markers in acutely suicidal patients. 1. Comparison of serotonergic platelet measures between suicidal individuals, nonsuicidal patients with major depression and healthy subjects. J Neural Transm. 2007; 114: 479–87.
10.
Jaim-Etcheverry G. 2-chloroethylamines (DSP-4 and xylamine). Toxic action on noradrenergic neurons. W: Hight selective neurotoxins. Basic and clinical application. Kostrzewa RM – Human Press, Totowa, New Jersey 1998; 131–140.
11.
Dooley DJ, Moglinicka E, Dolini-Stula A, Waechter F, Truog A, Wood J. Functional supersensitivity to adrenergic agonist in the rat after DSP-4, a selective noradrenergic neurotoxin. Psychopharmacol. 1983; 81: 1–5.
12.
Korzeniewska-Rybicka I, Płazik A. Analgesic effect of antidepressant drugs. Pharmacol Biochem Behav 1998; 111: 503–508.
13.
Acton J, McKenna JE, Melzack R. Amitriptiline products analgesia in the formalin pain test. Exp Neurol. 1992; 117: 94–96.
14.
Quednow BB, Westheide J, Kuhn KU et all. Normal prepulse In hibition and habituation of acoustic startle response in suicidal depressive patients without psychotic symptoms. J Affect Disord. 2006; 92: 299–303.
15.
Loomer HP, Saunders JC, Kline NS. A clinical and pharmacodynamic evaluation of Iproniazid as a psychic energizer. Psychiatr Res Rep Amer Psychiatr Ass. 1957; 8: 129–141.
16.
Dietz BM, Mahady GB, Pauli GF, Farnsworth NR. Valerian extract and valerenic acid are partial agonists of the 5-HT5a receptor in vitro. Mol Brain Res. 2005; 138:191–7.
17.
Bespalov A, Dumpis M, Piotrovsky L, Zvartau E. Excitatory amino acid receptor antagonist kynurenic acid attenuates rewarding potential of morphine. Eur J Pharmacol. 1994; 264: 233–239.
18.
Wiborg O, Sanchez C. Escitalopram: a comparative in vitro study of 5-HT uptake inhibition and binding in a COS-1 cell line expressing human 5-HT transporter. Eur Neuropsychopharmacol. 2002; 12: 229.
19.
Archer T, Jonsson G, Minor BG, Post C. Noeadrenergic-serotoninergic interactions and nociception in the rat. Eur J Pharmacol. 1986; 120: 295–307.
20.
Glaum SR, Proudfit HK, Anderson EG. 5-HT3 receptors modulate spinal nociceptive reflexes. Brain Res. 1990; 510: 12–16.
21.
Sasaki M, Ishozaki K, Obata H. Goto F. Effects of 5-HT2 and 5-HT3 receptors onmodulation of nociceptive transmission in rat spinal cord, according to the formalin test. Eur J Pharmacol. 2001; 424: 45–52.
22.
Peng YB, Wu J, Willis WD, Kenshalo DR. GABA(A) and 5-HT(3) receptors are involved in dorsal root reflexes: possible role in periaqueductal gray decending inhibition. J Neurophysiol. 2001; 86: 49–58.
23.
Peng YB, Lin Q, Willis WD. The role of 5-HT3 receptors in periaqueductal gray-induced inhibition of nociceptive dorsal horn neurons in rats. J Pharmacol Exp Ther. 1996; 276: 116–124.
24.
Xiao DQ, Zhu JX, Tang JS, Jia H. 5-hydroxytryptamine 1A (5-HT1A) but not 5-HT3 receptor is involved in mediating the nucleus submedius 5-HT-evoked anti- nociception in the rat. Brain Res. 2005; 1046: 38–44.
25.
Zeitz KP, Guy N, Malmberg AB, Dirajlal S, Martin WJ, Sun L, Bonhaus DW, Stucky CL, Julius D, Basbaum AI. The 5-HT3 subtype of serotonin receptor contributes to nociceptive processing via a novel subset of myelinated and unmyelinated nociceptors. J Neurosci. 2002; 22: 1010– 1019.
26.
Giordano J, Dyche J. Differential analgesic actions of serotonin 5-HT3 receptor antagonists in the mouse. Neuropharamcology 1989; 28: 423–427.
27.
Sufka KJ, Schomburg FM, Giordano J. Receptor mediation of 5-HT-induced inflammation and nociception in rats. Pharmacol Biochem Behav. 1992; 41: 53–56.
28.
Kesim M, Duman EN, Kadioglu M, Yaris E, Kalyoncu NI, Erciyes N. The different roles of 5-HT2 and 5-HT3 receptors on antinociceptive effect of paroxetine in chemical stimuli in mice. J Pharmacol Sci. 2005; 97: 61–66.
29.
McEwen BS, Kalia M. The role of corticosteroids and stress in chronic pain conditions. Metabolism. 2010; 59: 9–15.
30.
Bleakman D, Alt A, Nisenbaum ES. Glutamate receptors and pain. Seminars in Cell & Developmental Biology 2006; 17: 592–604.
31.
Guindon J, Hohmann AG. The Endocannabinoid System and Pain CNS Neurol Disord Drug Targets. 2009; 8: 403–421.
32.
Johannessen Landmark C. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 2008; 22: 27–47.
33.
Sawynok J, Esser MJ, Reid AR. Antidepressants as analgesics: an overview of central and peripheral mechanisms of action. J Psychiatry Neurosci. 2001; 26: 21–29.
34.
Le Bars D, Gozariu M, Cadden SW. Animal models of nociception. Pharmacol Rev. 2001; 53: 597–652.
35.
Coderre TJ, Fundytus ME, McKenna JE, Dalal S, Melzack R. The formalin test: a validation of the weighted-scores method of behavioural pain rating. Pain 1995; 54: 43–50.
| eISSN: | 1898-7516 |
| ISSN: | 1898-2395 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
